艾滋病不治会早死，早治才康复 艾滋病不治会早死，早治才康复 艾滋病不治会早死，早治才康复 艾滋病不治会早死，早治才康复
 |
| 图示∶2011年5月正式出版的《中国特色医疗金鉴》登载的刘君主任及其机构事迹 |
| |
|
|
Effective AIDS vaccine is still the commercial long way to go - visit the Spanish expert, Dr. Quiroz
October 6, 2011 23:32:03
Source: Xinhua
Xinhua Madrid, October 6 interview with Xinhua: the commercialization of effective AIDS vaccine is still a long way to go - visit the Spanish expert, Dr. Quiroz
Xinhua News Agency reporters Feng Junwei and Bao Daoyuan Xie Yuzhi
Madrid, Spain, Gregory Omar Lannion Hospital announced last week, hospital developed a new AIDS vaccine MVA-B has entered the second phase of human testing, the news caused great concern to the international medical community . In this regard, the project's chief expert Hu green card Luo Siji Dr. Ross recently told the Xinhua News Agency reporter interview that the vaccine needs to conduct more tests, its commercial production is still a long way to go.
MVA-B as the main development of the smallpox vaccine, there is no added replication of HIV genes. The vaccine is expected to weaken the AIDS virus, it can only lead to "minor chronic infection."
"The second phase of testing will take three to five years, after the third stage to determine whether the study. The third stage will take three to four years, so even if all goes well, we need at least to 1989 has AIDS vaccine. "Quiroz said Dr..
"HIV is a 'stupid' the virus, stupid is a very poor quality of its genetic material, can not be reproduced with a constant but low quality is that it has an advantage - it's on and the next generation generation, then the next generation is different, "explains Dr. Quiroz. "We are the body of certain proteins and virus immune response, but after a generation of HIV variants and variants, and later changed completely, so we developed a few months ago for the prevention of HIV virus may be the face of new drugs no effect, only to see it continue to multiply and harm. "
Dr. Quiroz, said the new vaccine in the 1970s had used the eradication of smallpox. This vaccine is a genetically modified smallpox virus, we extract some of the genes, and will not lead to the introduction of some of the HIV AIDS virus genes.
On human testing, he said, volunteers are all tested, and many of them family members or friends who have been infected with HIV. These volunteers will undergo three separate experimental stage, has now completed the first phase is to see whether the vaccine have side effects. The results for the second phase of testing cleared the road. He expressed the hope that the next phase III of the test.
"The second stage, we mainly observe the immune system response, to see how the immune system to help people solve problems, while we have to confirm whether there are any negative effects exist. The third stage will be the preclinical stage, the key is how the vaccine Can those who have been vaccinated and have exposure to people who get the virus under immune. "
According to Dr. Quiroz, they will be infected with HIV in a number of people who started the second study to see whether the vaccine produced sufficient immune effects were no longer sufficient to allow the infection to antiretroviral therapy, and their immune response can control virus replication to stop or slow down the replication rate that does not harm the infected person's immune system level.
新华网马德里１０月６日电 专访：有效艾滋病疫苗的商业化仍有很长的路要走——访西班牙专家基罗斯博士
新华社记者冯俊伟 报道员谢宇智
西班牙马德里的格雷戈里奥·马拉尼翁医院上周宣布，该院研制的一种全新艾滋病疫苗ＭＶＡ－Ｂ已进入人体测试的第二阶段，这一消息引起国际医学界的极大关注。对此，项目首席专家胡安·卡洛斯·基罗斯博士日前在接受新华社记者专访时表示，对这种疫苗还需进行更多测试，其投入商业化生产仍有很长的路要走。
ＭＶＡ－Ｂ以天花疫苗为主体研制，添加了没有复制能力的艾滋病病毒基因。这种疫苗有望弱化艾滋病病毒，使它只能引发“轻微慢性感染”。
“第二阶段测试将需要３至５年，之后再判断能否进行第三阶段的研究。第三阶段还将需要３至４年时间。所以，即使一切顺利，我们至少还需要八九年才能拥有艾滋病疫苗。”基罗斯博士说。
“艾滋病病毒是一种‘愚蠢’的病毒，愚蠢是指其遗传物质质量非常差，不能以一个恒定的形式复制。但这种低质量却让它拥有了一个优势——它的上一代和下一代、再下一代都是不同的，”基罗斯博士解释说。“我们人体对某些蛋白质和病毒有免疫反应，但艾滋病病毒经过了一代代变异和变种，到后来完全改变了，所以我们在几个月前针对这一病毒研制的预防药物面对新病毒可能没有任何作用，只能眼看它继续繁殖和为害。”
基罗斯博士介绍说，新疫苗是在２０世纪７０年代消灭天花时曾使用过的。这种疫苗是经基因修改后的天花病毒，我们从中提取某些基因，并引入一些不会导致感染艾滋病的艾滋病病毒基因。
关于人体测试，他说，所有接受测试的都是志愿者，其中很多人的家人或朋友曾受艾滋病病毒感染。这些志愿者将经历独立的三个实验阶段，现已完成的第一阶段主要是看疫苗是否有副作用。实验结果为第二阶段测试扫清了道路。他表示希望今后能进行第三阶段的测试。
“第二阶段，我们主要观察免疫系统的应答，看看免疫系统如何帮助人们解决问题，另外我们还要确认是否有任何负面效应的存在。而第三阶段将是临床前阶段，主要是看疫苗能否让那些接种过疫苗并曾暴露在病毒下的人获得免疫。”
据基罗斯博士介绍，他们还将在一些被艾滋病病毒感染的人身上展开第二项研究，看疫苗能否产生足够的免疫效果足以让感染者不用再接受抗逆转录病毒药物治疗，以及他们的免疫应答能否控制病毒，使其停止复制，或者使复制速度减缓到不伤害受感染者的免疫系统的程度。
